IL1B and metabolic dysfunction-associated steatotic liver disease: In fructose-induced nonalcoholic fatty liver disease (NAFLD) models, betaine treatment has been shown to significantly inhibit levels of pro-inflammatory cytokines, including IL-1β, in a dose-independent manner (17).